Liver Diseases  >>  linifanib (ABT-869)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linifanib (ABT-869) / AbbVie
NCT01009593 / 2009-013435-38: Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Terminated
3
1035
Japan, US, Canada, Europe, RoW
ABT-869, Sorafenib
Abbott
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases, Neoplasms by Histologic Type, Digestive System Neoplasms, Carcinoma, Liver Neoplasms, Neoplasms, Neoplasms by Site, Digestive System Diseases, Adenocarcinoma, Neoplasms, Glandular and Epithelial
07/12
07/12

Download Options